Research ExplorerPublicationsThe role of anti-thymocyte globulin in allogeneic stem cell ...

The role of anti-thymocyte globulin in allogeneic stem cell transplantation (HSCT) from HLA-matched unrelated donors (MUD) for secondary AML in remission: a study from the ALWP /EBMT

Standard

The role of anti-thymocyte globulin in allogeneic stem cell transplantation (HSCT) from HLA-matched unrelated donors (MUD) for secondary AML in remission: a study from the ALWP /EBMT. / Nagler, Arnon; Labopin, Myriam; Kröger, Nicolaus; Schroeder, Thomas; Gedde-Dahl, Tobias; Eder, Matthias; Franke, Georg-Nikolaus; Blau, Igor Wolfgang; Salmenniemi, Urpu; Socie, Gerard; Schetelig, Johannes; Stelljes, Matthias; Ciceri, Fabio; Mohty, Mohamad.

In: BONE MARROW TRANSPL, Vol. 58, No. 12, 12.2023, p. 1339-1347.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Nagler, A, Labopin, M, Kröger, N, Schroeder, T, Gedde-Dahl, T, Eder, M, Franke, G-N, Blau, IW, Salmenniemi, U, Socie, G, Schetelig, J, Stelljes, M, Ciceri, F & Mohty, M 2023, 'The role of anti-thymocyte globulin in allogeneic stem cell transplantation (HSCT) from HLA-matched unrelated donors (MUD) for secondary AML in remission: a study from the ALWP /EBMT', BONE MARROW TRANSPL, vol. 58, no. 12, pp. 1339-1347. https://doi.org/10.1038/s41409-023-02095-0

APA

Nagler, A., Labopin, M., Kröger, N., Schroeder, T., Gedde-Dahl, T., Eder, M., Franke, G-N., Blau, I. W., Salmenniemi, U., Socie, G., Schetelig, J., Stelljes, M., Ciceri, F., & Mohty, M. (2023). The role of anti-thymocyte globulin in allogeneic stem cell transplantation (HSCT) from HLA-matched unrelated donors (MUD) for secondary AML in remission: a study from the ALWP /EBMT. BONE MARROW TRANSPL, 58(12), 1339-1347. https://doi.org/10.1038/s41409-023-02095-0

Vancouver

Nagler A, Labopin M, Kröger N, Schroeder T, Gedde-Dahl T, Eder M et al. The role of anti-thymocyte globulin in allogeneic stem cell transplantation (HSCT) from HLA-matched unrelated donors (MUD) for secondary AML in remission: a study from the ALWP /EBMT. BONE MARROW TRANSPL. 2023 Dec;58(12):1339-1347. https://doi.org/10.1038/s41409-023-02095-0

Bibtex

@article{0aa5938fba2c48709facc6b115add1b2,
title = "The role of anti-thymocyte globulin in allogeneic stem cell transplantation (HSCT) from HLA-matched unrelated donors (MUD) for secondary AML in remission: a study from the ALWP /EBMT",
abstract = "We compared outcomes, of 1609 patients with secondary acute myeloid leukemia (sAML) undergoing allogeneic transplantation (HSCT) in first complete remission (CR1) from matched unrelated donors (MUD) from 2010 to 2021, receiving or not receiving anti-thymocyte globulin (ATG) (ATG-1308, no ATG-301). Median age was 60.9 (range, 18.5-77.8) and 61.1 (range, 21.8-75.7) years, (p = 0.3). Graft versus host disease (GVHD) prophylaxis was cyclosporin-A with methotrexate (41%) or mycophenolate mofetil (38.2%), without significant differences between groups. Day 28, engraftment (ANC > 0.5 × 109/L) was 92.3% vs 95.3% (p = 0.17), respectively. On multivariate analysis, ATG was associated with lower incidence of grade II-IV and grade III-IV acute GVHD (p = 0.002 and p = 0.015), total and extensive chronic GVHD (p = 0.008 and p < 0.0001), and relapse incidence (RI) (p = 0.039), while non-relapse mortality (NRM) did not differ (p = 0.51). Overall survival (OS), and GVHD-free, relapse-free survival (GRFS) were significantly higher in the ATG vs no ATG group, HR = 0.76 (95% CI 0.61-0.95, p = 0.014) and HR = 0.68 (95% CI 0.57-0.8, p < 0.0001), with a tendency for better leukemia-free survival (LFS), HR = 0.82 (95% CI 0.67-1, p = 0.051). The main causes of death were the original disease, infection, and GVHD. In conclusion, ATG reduces GVHD and improves LFS, OS, and GRFS in sAML patients without increasing the RI, despite sAML being a high-risk disease.",
keywords = "Humans, Middle Aged, Antilymphocyte Serum/therapeutic use, Unrelated Donors, Hematopoietic Stem Cell Transplantation/adverse effects, Leukemia, Myeloid, Acute/drug therapy, Graft vs Host Disease/etiology, Recurrence, Chronic Disease, Retrospective Studies, Transplantation Conditioning/adverse effects",
author = "Arnon Nagler and Myriam Labopin and Nicolaus Kr{\"o}ger and Thomas Schroeder and Tobias Gedde-Dahl and Matthias Eder and Georg-Nikolaus Franke and Blau, {Igor Wolfgang} and Urpu Salmenniemi and Gerard Socie and Johannes Schetelig and Matthias Stelljes and Fabio Ciceri and Mohamad Mohty",
note = "{\textcopyright} 2023. The Author(s), under exclusive licence to Springer Nature Limited.",
year = "2023",
month = dec,
doi = "10.1038/s41409-023-02095-0",
language = "English",
volume = "58",
pages = "1339--1347",
journal = "BONE MARROW TRANSPL",
issn = "0268-3369",
publisher = "NATURE PUBLISHING GROUP",
number = "12",

}

RIS

TY - JOUR

T1 - The role of anti-thymocyte globulin in allogeneic stem cell transplantation (HSCT) from HLA-matched unrelated donors (MUD) for secondary AML in remission: a study from the ALWP /EBMT

AU - Nagler, Arnon

AU - Labopin, Myriam

AU - Kröger, Nicolaus

AU - Schroeder, Thomas

AU - Gedde-Dahl, Tobias

AU - Eder, Matthias

AU - Franke, Georg-Nikolaus

AU - Blau, Igor Wolfgang

AU - Salmenniemi, Urpu

AU - Socie, Gerard

AU - Schetelig, Johannes

AU - Stelljes, Matthias

AU - Ciceri, Fabio

AU - Mohty, Mohamad

N1 - © 2023. The Author(s), under exclusive licence to Springer Nature Limited.

PY - 2023/12

Y1 - 2023/12

N2 - We compared outcomes, of 1609 patients with secondary acute myeloid leukemia (sAML) undergoing allogeneic transplantation (HSCT) in first complete remission (CR1) from matched unrelated donors (MUD) from 2010 to 2021, receiving or not receiving anti-thymocyte globulin (ATG) (ATG-1308, no ATG-301). Median age was 60.9 (range, 18.5-77.8) and 61.1 (range, 21.8-75.7) years, (p = 0.3). Graft versus host disease (GVHD) prophylaxis was cyclosporin-A with methotrexate (41%) or mycophenolate mofetil (38.2%), without significant differences between groups. Day 28, engraftment (ANC > 0.5 × 109/L) was 92.3% vs 95.3% (p = 0.17), respectively. On multivariate analysis, ATG was associated with lower incidence of grade II-IV and grade III-IV acute GVHD (p = 0.002 and p = 0.015), total and extensive chronic GVHD (p = 0.008 and p < 0.0001), and relapse incidence (RI) (p = 0.039), while non-relapse mortality (NRM) did not differ (p = 0.51). Overall survival (OS), and GVHD-free, relapse-free survival (GRFS) were significantly higher in the ATG vs no ATG group, HR = 0.76 (95% CI 0.61-0.95, p = 0.014) and HR = 0.68 (95% CI 0.57-0.8, p < 0.0001), with a tendency for better leukemia-free survival (LFS), HR = 0.82 (95% CI 0.67-1, p = 0.051). The main causes of death were the original disease, infection, and GVHD. In conclusion, ATG reduces GVHD and improves LFS, OS, and GRFS in sAML patients without increasing the RI, despite sAML being a high-risk disease.

AB - We compared outcomes, of 1609 patients with secondary acute myeloid leukemia (sAML) undergoing allogeneic transplantation (HSCT) in first complete remission (CR1) from matched unrelated donors (MUD) from 2010 to 2021, receiving or not receiving anti-thymocyte globulin (ATG) (ATG-1308, no ATG-301). Median age was 60.9 (range, 18.5-77.8) and 61.1 (range, 21.8-75.7) years, (p = 0.3). Graft versus host disease (GVHD) prophylaxis was cyclosporin-A with methotrexate (41%) or mycophenolate mofetil (38.2%), without significant differences between groups. Day 28, engraftment (ANC > 0.5 × 109/L) was 92.3% vs 95.3% (p = 0.17), respectively. On multivariate analysis, ATG was associated with lower incidence of grade II-IV and grade III-IV acute GVHD (p = 0.002 and p = 0.015), total and extensive chronic GVHD (p = 0.008 and p < 0.0001), and relapse incidence (RI) (p = 0.039), while non-relapse mortality (NRM) did not differ (p = 0.51). Overall survival (OS), and GVHD-free, relapse-free survival (GRFS) were significantly higher in the ATG vs no ATG group, HR = 0.76 (95% CI 0.61-0.95, p = 0.014) and HR = 0.68 (95% CI 0.57-0.8, p < 0.0001), with a tendency for better leukemia-free survival (LFS), HR = 0.82 (95% CI 0.67-1, p = 0.051). The main causes of death were the original disease, infection, and GVHD. In conclusion, ATG reduces GVHD and improves LFS, OS, and GRFS in sAML patients without increasing the RI, despite sAML being a high-risk disease.

KW - Humans

KW - Middle Aged

KW - Antilymphocyte Serum/therapeutic use

KW - Unrelated Donors

KW - Hematopoietic Stem Cell Transplantation/adverse effects

KW - Leukemia, Myeloid, Acute/drug therapy

KW - Graft vs Host Disease/etiology

KW - Recurrence

KW - Chronic Disease

KW - Retrospective Studies

KW - Transplantation Conditioning/adverse effects

U2 - 10.1038/s41409-023-02095-0

DO - 10.1038/s41409-023-02095-0

M3 - SCORING: Journal article

C2 - 37660157

VL - 58

SP - 1339

EP - 1347

JO - BONE MARROW TRANSPL

JF - BONE MARROW TRANSPL

SN - 0268-3369

IS - 12

ER -